Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Erding – page 51

1 344 clinical trials in Erding, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erding at a glance
1 344
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 344 trials in Erding

Open in trial search

Pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A Study of Ponsegromab Combined with Chemotherapy for Adults with Pancreatic Cancer that has Spread and Caused Weight Loss

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ponsegromab
  • Sponsor:Pfizer Inc.

Testing continuous versus intermittent treatment with cetuximab, fluorouracil, folinic acid, and irinotecan in patients with newly diagnosed metastatic colorectal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Angina pectoris

Not yet recruiting

A Study of Encoberminogene Rezmadenovec Gene Therapy for Patients with Refractory Angina Due to Coronary Artery Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Flurpiradaz F 18
  • Sponsor:Xylocor Therapeutics Inc.

Pharyngitis

Not yet recruiting

Study of benzydamine hydrochloride and dichlorobenzyl alcohol lozenges for treating acute pharyngitis symptoms

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:2,4 dichlorobenzyl alcohol
  • Sponsor:MEDICE Arzneimittel Puetter GmbH & Co. KG

Myasthenia gravis

Not yet recruiting

Study of TOL2 safety and immune response in patients with generalized myasthenia gravis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glucose
  • Sponsor:Bonsai Biotherapeutics AB
Countries:GermanyGermany
  • Participants:18–64 years · Healthy volunteers
  • Substances:Perflutren
  • Sponsor:Solstice Pharmaceuticals B.V.

Retinal dystrophy

Not yet recruiting

Safety and early effectiveness study of VG801 subretinal injection in patients with ABCA4 mutation-associated retinal dystrophy

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:VG801-1
  • Sponsor:VeonGen Therapeutics GmbH

Bronchiectasis

Not yet recruiting

Study of Nebulized Human Normal Immunoglobulin (CSL787) for Adults with Non-cystic Fibrosis Bronchiectasis to Find Best Dose and Test Safety

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:CSL Behring LLC

Study of Empagliflozin to Improve Heart Function in Adults with Pulmonary Arterial Hypertension

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin
  • Sponsor:Philipps-Universitaet Marburg

Hepatic lesion

Not yet recruiting

Safety and Effectiveness of Intravenous Sonazoid for Contrast-Enhanced Liver Ultrasound in Children with Focal Liver Lesions

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Perflubutane
  • Sponsor:GE Healthcare Limited

Dementia

Not yet recruiting

Study on Efgartigimod for Patients with Autoimmune Dementia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Erding

What the registry says about research in the country

01 Hematologic Disorders

Innovative research focusing on Myelodysplastic Syndrome (MDS), comparing novel therapeutic approaches for patients with lower-risk conditions. The studies aim to evaluate treatment effectiveness in managing blood cell production disorders.

  • Lower-risk MDS management
  • Blood cell production therapy
  • Treatment conversion studies

Current trials are investigating comparative effectiveness of different therapeutic agents in managing transfusion dependency.

02 Blood Disorders

Advanced research into polycythemia vera treatment resistance, utilizing artificial intelligence to predict treatment outcomes. Studies focus on understanding hydroxyurea resistance patterns in affected patients.

  • Treatment resistance evaluation
  • AI-driven predictions
  • Therapeutic monitoring

Research combines traditional clinical approaches with modern machine learning techniques to optimize treatment strategies.

03 Cardiovascular Medicine

Groundbreaking research on acute coronary syndrome and atrial fibrillation, exploring optimized antiplatelet therapy protocols. Studies evaluate new approaches for patients undergoing percutaneous coronary intervention.

  • Antiplatelet therapy optimization
  • Cardiac intervention outcomes
  • Bleeding risk management

Investigations focus on balancing therapeutic efficacy with safety in complex cardiac conditions.

04 Advanced Myelofibrosis

Clinical investigations of intermediate and high-risk myelofibrosis, exploring combination therapies and novel treatment approaches. Research aims to establish optimal dosing strategies for enhanced patient outcomes.

  • Combination therapy assessment
  • Treatment tolerability studies
  • Dose optimization research

Studies focus on developing safer and more effective treatment protocols for advanced stages of the disease.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.